Otonomy To Challenge Multi-Dose Ear Drops With Otiprio Expansion Plans
Executive Summary
Otonomy will file for expanded US approval of Otiprio for use in swimmer’s ear on the back of positive top-line Phase III data – the product has the potential to improve on current treatments in terms of dosing, and the news sent its share price up by more than 10%.
You may also be interested in...
Keeping Track: Delay (For Celgene), Delay (For Allergan), Goose! (Approval For Lilly)
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Merck's Follow-On Insulin Edges Closer To Market; Braeburn Submits Another Buprenorphine Depot
The latest drug development news and highlights from our FDA Performance Tracker.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.